Lurbinectedin 4 MG Injection — RxCUI 2374733
RxNorm drug concept · Semantic clinical drug
RxCUI 2374733
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2374733
Official nameLurbinectedin 4 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)1,194 prescriptions · 22 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Lurbinectedin Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Zepzelca (lurbinectedin) is a chemotherapy specifically approved for small cell lung cancer — a fast-growing type of lung cancer. Depending on your situation, it may be used as a m...
- What exactly is Zepzelca being used to treat in my situation?
- Zepzelca is not a pill you take at home — it's given as an intravenous (IV) infusion at a clinic or infusion center. Each session takes about 60 minutes, and you'll receive it once...
- How will I get this medication, and how often?
🕸️ Concept Web — How Lurbinectedin 4 MG Injection Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Lurbinectedin 4 MG Injection
RxCUI 2374733 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Lurbinectedin
2374729IN
-
Lurbinectedin
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Zepzelca
2374734BN
-
Zepzelca
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Lurbinectedin Injection
2374732SCDF -
Lurbinectedin Injectable Product
2374731SCDG -
Lurbinectedin Injection [Zepzelca]
2374736SBDF -
Zepzelca Injectable Product
2374737SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Lurbinectedin Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Lurbinectedin 4 MG
2374730SCDC -
Lurbinectedin 4 MG Injection [Zepzelca]
2374738SBD -
Lurbinectedin 4 MG [Zepzelca]
2374735SBDC
-
Lurbinectedin 4 MG
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Lurbinectedin 4 MG
SCDC · 2374730 -
Lurbinectedin Injection
SCDF · 2374732 -
Lurbinectedin Injectable Product
SCDG · 2374731
Brand-Name Concepts
-
Lurbinectedin 4 MG Injection [Zepzelca]
SBD · 2374738 -
Lurbinectedin 4 MG [Zepzelca]
SBDC · 2374735 -
Lurbinectedin Injection [Zepzelca]
SBDF · 2374736 -
Zepzelca Injectable Product
SBDG · 2374737 -
Zepzelca
BN · 2374734
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 2374733 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 68727-0712-01 | 8 mL in 1 VIAL, SINGLE-DOSE (68727-712-01) | ZEPZELCA | Jazz Pharmaceuticals, Inc. | 2020-06-15 |
Observed labelers:
Jazz Pharmaceuticals, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J9223 | Inj. lurbinectedin, 0.1 mg | 1 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.